Results 101 to 110 of about 5,314 (201)

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis

Frontiers in Gastroenterology
IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (
Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing   +6 more
doaj   +1 more source

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy

Pathogens
Prior to the Food and Drug Administration approval of ledipaspavir/sofosbuvir (Harvoni®) in 2014, the treatment of hepatitis C was interferon plus or minus ribavirin.
Christopher Hartley, Trung Van, Wikrom Karnsakul   +2 more
doaj   +1 more source

STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR IN BULK AND TABLET DOSAGE FORMS [PDF]

, 2020
Objective: The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase high-performance liquid chromatography method for the simultaneous estimation of sofosbuvir, velpatasvir, and voxilaprevir ...
D, GOWRI SANKAR, PADMINI M, VENKATA
core   +1 more source

Issue Information

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 11, November 2025.
wiley   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source

Velpatasvir [PDF]

, 2020
openaire   +1 more source

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Scientific Reports
Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K ...
Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido   +11 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [PDF]

, 2016
Afdhal, N, Agarwal, K, Asselah, T, Berg, T, Bourliere, M, Braeu, N, Brainard, DM, Conway, B, Cooper, C, Dvory-Sobol, H, Foster, GR, Gane, EJ, Gordon, SC, Han, L, Investigators, AA, Lawitz, E, Mangia, A, Mazzotta, F, McHutchison, JG, McNally, J, Mo, H, Osinusi, A, Patel, K, Pianko, S, Reau, N, Roberts, SK, Rosenberg, W, Ruane, P, Shiffman, ML, Stedman, CAM, Sulkowski, M, Thompson, A, Towner, WJ, Tran, TT, Wang, J, Zeuzem, S   +35 more
core   +1 more source

Assessing the Frequency of Cytopenias in Patients with Hepatitis C Therapy: An Analytical Cross-Sectional Study

Journal of Gandhara Medical and Dental Sciences
OBJECTIVES This study aimed to determine the frequency of cytopenias among patients receiving hepatitis C therapy and to examine their relationship with different treatment regimens METHODOLOGY This analytical cross-sectional study was conducted ...
Shadman Ahmad Jan, Naveed Iqbal, Ilyas Muhammad, Zahid Ullah, Ijaz Hussain   +4 more
doaj  

Method development and validation of a new RP-UFLC method for the simultaneous estimation of Sofosbuvir and Velpatasvir in tablet dosage form using an internal standard [PDF]

Sofosbuvir is an anti-viral drug used for the treatment of chronic hepatitis C virus infection and Velpatasvir is also an anti-viral drug used for the inhibition of hepatitis C virus and both the drugs acts directly.
Mukthinuthalapati Mathrusri Annapurna, Priyanka Vallabh Deulkar   +1 more
core   +1 more source